Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta, Roberto Borea, Andreia Coelho, et al.
Critical Reviews in Oncology/Hematology (2017) Vol. 113, pp. 256-267
Open Access | Times Cited: 189

Showing 26-50 of 189 citing articles:

Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR–MAPK cascades
Taisuke Hoshi, Saori Watanabe Miyano, Hideki Watanabe, et al.
Biochemical and Biophysical Research Communications (2019) Vol. 513, Iss. 1, pp. 1-7
Open Access | Times Cited: 70
Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway
Yuhong Lü, Yanfeng Liu, Sebastian Oeck, et al.
Cancer Research (2020) Vol. 80, Iss. 21, pp. 4655-4667
Open Access | Times Cited: 66
Nongenetic engineering strategies for regulating receptor oligomerization in living cells
Jingying Li, Liping Wang, Jin‐Miao Tian, et al.
Chemical Society Reviews (2020) Vol. 49, Iss. 5, pp. 1545-1568
Closed Access | Times Cited: 61
Compounds from Natural Sources as Protein Kinase Inhibitors
Andrea Baier, Ryszard Szyszka
Biomolecules (2020) Vol. 10, Iss. 11, pp. 1546-1546
Open Access | Times Cited: 60
The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
Navid Sobhani, Chunmei Fan, Pedro O. Flores-Villanueva, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 2011-2011
Open Access | Times Cited: 57
Enhancing Immunity with Nanomedicine: Employing Nanoparticles to Harness the Immune System
Cátia T. Perciani, Lewis Liu, Laurence M. Wood, et al.
ACS Nano (2020) Vol. 15, Iss. 1, pp. 7-20
Closed Access | Times Cited: 51
Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2
Guangyan Du, Jie Jiang, Qibiao Wu, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 29, pp. 15905-15911
Open Access | Times Cited: 43
Vascular endothelial growth factors and placenta growth factor in retinal vasculopathies: Current research and future perspectives
Joana Mesquita, João Paulo Castro Sousa, Sara Vaz-Pereira, et al.
Cytokine & Growth Factor Reviews (2017) Vol. 39, pp. 102-115
Open Access | Times Cited: 53
Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions
Francesca Battaglin, Madiha Naseem, Alberto Puccini, et al.
Cancer Cell International (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 53
Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
Teresa Alonso‐Gordoa, Laura García‐Bermejo, Enrique Grande, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 8, pp. 1901-1901
Open Access | Times Cited: 49
Distinct molecular etiologies of male and female hepatocellular carcinoma
Heini M. Natri, Melissa Wilson, Kenneth H. Buetow
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 47
FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
Ying Yang, Tingting Lü, Ziming Li, et al.
Cell Adhesion & Migration (2020) Vol. 14, Iss. 1, pp. 82-95
Open Access | Times Cited: 41
Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing.
Weiquan Gu, Jie Yang, Yong Wang, et al.
American Journal of Cancer Research (2021) Vol. 11, Iss. 8, pp. 3893-3906
Closed Access | Times Cited: 41
Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer
Laura Pacini, Andrew Jenks, Nadia Carvalho Lima, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 1154-1154
Open Access | Times Cited: 40
Biological Significance and Targeting of the FGFR Axis in Cancer
Athina‐Myrto Chioni, Richard Grose
Cancers (2021) Vol. 13, Iss. 22, pp. 5681-5681
Open Access | Times Cited: 40
XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes
Sheetal Rajpal, Ankit Rajpal, Manoj Agarwal, et al.
Biomedical Signal Processing and Control (2023) Vol. 84, pp. 104979-104979
Closed Access | Times Cited: 16
Molecular modeling of pyrrolo-pyrimidine based analogs as potential FGFR1 inhibitors: a scientific approach for therapeutic drugs
Ali Raza, Tahir Ali Chohan, Muhammad Sarfraz, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 41, Iss. 23, pp. 14358-14371
Closed Access | Times Cited: 14
Targeting Protein–Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches
Alessandra Monti, Luigi Vitagliano, Andrea Caporale, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7842-7842
Open Access | Times Cited: 14
<p>Improving The Oral Absorption Of Nintedanib By A Self-Microemulsion Drug Delivery System: Preparation And In Vitro/In Vivo Evaluation</p>
Hongfei Liu, Jiaao Mei, Ying Xu, et al.
International Journal of Nanomedicine (2019) Vol. Volume 14, pp. 8739-8751
Open Access | Times Cited: 43
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
Navid Sobhani, Anna Ianza, Alberto D’Angelo, et al.
Cells (2018) Vol. 7, Iss. 7, pp. 76-76
Open Access | Times Cited: 42
Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1–3)
Abdellah Yamani, Daria Zdżalik-Bielecka, Joanna Lipner, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112990-112990
Closed Access | Times Cited: 37
Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
Hengyu Lu, Chen Liu, Hung Huynh, et al.
Oncotarget (2020) Vol. 11, Iss. 3, pp. 265-281
Open Access | Times Cited: 36
In search of novel inhibitors of anti-cancer drug target fibroblast growth factor receptors: Insights from virtual screening, molecular docking, and molecular dynamics
A. M. U. B. Mahfuz, Md. Arif Khan, Suvro Biswas, et al.
Arabian Journal of Chemistry (2022) Vol. 15, Iss. 7, pp. 103882-103882
Open Access | Times Cited: 20
Discovery of 1,6-Naphthyridin-2(1H)-one Derivatives as Novel, Potent, and Selective FGFR4 Inhibitors for the Treatment of Hepatocellular Carcinoma
Xiaomeng Zhang, Shaobin Wang, Jianfeng Ji, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7595-7618
Closed Access | Times Cited: 20
Receptor clustering by a precise set of extracellular galectins initiates FGFR signaling
Dominika Żukowska, Aleksandra Gędaj, Natalia Porębska, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 4
Open Access | Times Cited: 12

Scroll to top